Moderna, Inc. (MRNA) saw its stock plummet by 5.06% in pre-market trading on Thursday, following reports that the Trump administration is considering withdrawing funding for the company's $590 million bird flu vaccine contract.
The contract, awarded by the Biden administration in its final days, aimed to advance the development of Moderna's messenger RNA (mRNA)-based bird flu vaccine. However, the new Trump administration is reevaluating the deal as part of a broader push to scrutinize spending on mRNA vaccines, a technology widely used during the COVID-19 pandemic.
According to reports, the potential loss of this significant funding could deal a blow to Moderna's future revenue and growth prospects, as the bird flu contract was seen as a significant part of its pipeline. Investors are likely concerned that without this funding, Moderna may struggle to advance the development of the vaccine, hampering its ability to diversify its revenue streams beyond COVID-19 vaccines.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。